PMC7748897_01
Response to treatment. (a) M protein levels after initiation of treatment with vemurafenib and cobimetinib at 0, 5, 9, 13, 16, 25, and 37 weeks. (b) Changes in kappa/lambda ratio at 0, 5, 9, 13, 16, 25, and 37 weeks. The beige box shows the normal range of the kappa/lambda ratio.
CRIHEM2020-8821415.001.jpg
PMC7748897_01_CRIHEM2020-8821415.001.jpg
fig1
His M protein levels and kappa/lambda ratio were as shown in Figure 1.